{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:48:35Z","timestamp":1791902915999,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1038\/ncprheum0619","type":"journal-article","created":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T13:04:24Z","timestamp":1190984664000},"page":"552-560","source":"Crossref","is-referenced-by-count":42,"title":["Drug Insight: cyclo-oxygenase-2 inhibitors\u2014a critical appraisal"],"prefix":"10.1038","volume":"3","author":[{"given":"Burkhard","family":"Hinz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertold","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Brune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncprheum0619_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 231: 232\u2013235","journal-title":"Nat New Biol"},{"key":"BFncprheum0619_CR2","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1172\/JCI114850","volume":"86","author":"JL Masferrer","year":"1990","unstructured":"Masferrer JL et al. (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86: 1375\u20131379","journal-title":"J Clin Invest"},{"key":"BFncprheum0619_CR3","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1073\/pnas.88.7.2692","volume":"88","author":"W Xie","year":"1991","unstructured":"Xie W et al. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 88: 2692\u20132696","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncprheum0619_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0014-5793(96)00604-7","volume":"390","author":"F Beiche","year":"1996","unstructured":"Beiche F et al. (1996) Upregulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390: 165\u2013169","journal-title":"FEBS Lett"},{"key":"BFncprheum0619_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJM200108093450607","volume":"345","author":"GA FitzGerald","year":"2001","unstructured":"FitzGerald GA and Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345: 433\u2013442","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/jpet.300.2.367","volume":"300","author":"B Hinz","year":"2002","unstructured":"Hinz B and Brune K (2002) Cyclooxygenase-2\u2014ten years later. J Pharmacol Exp Ther 300: 367\u2013375","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncprheum0619_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nrd1034","volume":"2","author":"RJ Flower","year":"2003","unstructured":"Flower RJ (2003) The development of COX2 inhibitors. Nat Rev Drug Discov 2: 179\u2013191","journal-title":"Nat Rev Drug Discov"},{"key":"BFncprheum0619_CR8","first-page":"623","volume":"48","author":"P Patrignani","year":"1997","unstructured":"Patrignani P et al. (1997) Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48: 623\u2013631","journal-title":"J Physiol Pharmacol"},{"key":"BFncprheum0619_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0009-9236(99)70073-1","volume":"65","author":"I Tegeder","year":"1999","unstructured":"Tegeder I et al. (1999) Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther 65: 533\u2013544","journal-title":"Clin Pharmacol Ther"},{"key":"BFncprheum0619_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0009-9236(03)00167-X","volume":"74","author":"B Hinz","year":"2003","unstructured":"Hinz B et al. (2003) Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 74: 222\u2013235","journal-title":"Clin Pharmacol Ther"},{"key":"BFncprheum0619_CR11","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nsb1196-927","volume":"3","author":"C Luong","year":"1996","unstructured":"Luong C et al. (1996) Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 3: 927\u2013933","journal-title":"Nat Struct Biol"},{"key":"BFncprheum0619_CR12","first-page":"413","volume-title":"Handbook of inflammation, Vol. 5. The Pharmacology of Inflammation","author":"K Brune","year":"1985","unstructured":"Brune K and Lanz R (1985) Pharmacokinetics of non-steroidal anti-inflammatory drugs. In Handbook of inflammation, Vol. 5. The Pharmacology of Inflammation, 413\u2013449 (Eds Bonta IL et al.) Amsterdam: Elsevier Science Publishers"},{"key":"BFncprheum0619_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/bmc.115","volume":"16","author":"U Werner","year":"2002","unstructured":"Werner U et al. (2002) Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 16: 56\u201360","journal-title":"Biomed Chromatogr"},{"key":"BFncprheum0619_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0009-9236(03)00120-6","volume":"74","author":"U Werner","year":"2003","unstructured":"Werner U et al. (2003) Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 74: 130\u2013137","journal-title":"Clin Pharmacol Ther"},{"key":"BFncprheum0619_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.21540","volume":"54","author":"B Hinz","year":"2006","unstructured":"Hinz B et al. (2006) More pronounced inhibition of cyclooxygenase-2, increase of blood pressure and decrease of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 54: 282\u2013291","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0619_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1124\/dmd.31.2.224","volume":"31","author":"AD Rodrigues","year":"2003","unstructured":"Rodrigues AD et al. (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 31: 224\u2013232","journal-title":"Drug Metab Dispos"},{"key":"BFncprheum0619_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00003088-200443070-00003","volume":"43","author":"G Scott","year":"2004","unstructured":"Scott G et al. (2004) Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 43: 467\u2013478","journal-title":"Clin Pharmacokinet"},{"key":"BFncprheum0619_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.bjp.0706078","volume":"144","author":"R Esser","year":"2005","unstructured":"Esser R et al. (2005) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144: 538\u2013550","journal-title":"Br J Pharmacol"},{"key":"BFncprheum0619_CR19","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520\u20131528","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","volume":"364","author":"TJ Schnitzer","year":"2004","unstructured":"Schnitzer TJ et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665\u2013674","journal-title":"Lancet"},{"key":"BFncprheum0619_CR21","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284: 1247\u20131255","journal-title":"J Am Med Assoc"},{"key":"BFncprheum0619_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/bmj.324.7349.1287","volume":"324","author":"P Juni","year":"2002","unstructured":"Juni P et al. (2002) Are selective COX2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 324: 1287\u20131288","journal-title":"BMJ"},{"key":"BFncprheum0619_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","volume":"369","author":"L Laine","year":"2007","unstructured":"Laine L et al. (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomized comparison. Lancet 369: 465\u2013473","journal-title":"Lancet"},{"key":"BFncprheum0619_CR24","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa021907","volume":"347","author":"FK Chan","year":"2002","unstructured":"Chan FK et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104\u20132110","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.amjmed.2005.04.031","volume":"118","author":"KC Lai","year":"2005","unstructured":"Lai KC et al. (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118: 1271\u20131278","journal-title":"Am J Med"},{"key":"BFncprheum0619_CR26","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1053\/j.gastro.2005.03.020","volume":"128","author":"L Maiden","year":"2005","unstructured":"Maiden L et al. (2005) A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128: 1172\u20131178","journal-title":"Gastroenterology"},{"key":"BFncprheum0619_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","volume":"3","author":"JL Goldstein","year":"2005","unstructured":"Goldstein JL et al. (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3: 133\u2013141","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFncprheum0619_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11882-006-0035-2","volume":"6","author":"C Picado","year":"2006","unstructured":"Picado C (2006) Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 6: 198\u2013202","journal-title":"Curr Allergy Asthma Rep"},{"key":"BFncprheum0619_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJM200101113440215","volume":"344","author":"B Dahlen","year":"2001","unstructured":"Dahlen B et al. (2001) Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 344: 142","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1067\/mai.2001.116290","volume":"108","author":"DD Stevenson","year":"2001","unstructured":"Stevenson DD and Simon RA (2001) Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 108: 47\u201351","journal-title":"J Allergy Clin Immunol"},{"key":"BFncprheum0619_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1365-2222.2001.01075.x","volume":"31","author":"A Szczeklik","year":"2001","unstructured":"Szczeklik A et al. (2001) Safety of a specific COX2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 31: 219\u2013225","journal-title":"Clin Exp Allergy"},{"key":"BFncprheum0619_CR32","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/art.10426","volume":"46","author":"KM Woessner","year":"2002","unstructured":"Woessner KM et al. (2002) The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 46: 2201\u20132206","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0619_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","volume":"364","author":"ME Farkouh","year":"2004","unstructured":"Farkouh ME et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675\u2013684","journal-title":"Lancet"},{"key":"BFncprheum0619_CR34","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/01.CIR.0000124715.27937.78","volume":"109","author":"ML Capone","year":"2004","unstructured":"Capone ML et al. (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109: 1468\u20131471","journal-title":"Circulation"},{"key":"BFncprheum0619_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092\u20131102","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071\u20131080","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa061652","volume":"355","author":"N Arber","year":"2006","unstructured":"Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B ; PreSAP Trial Investigators (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885\u2013895","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier NA et al. (2005) Complications of the COX2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081\u20131091","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR39","unstructured":"FDA (online 7 April 2005) FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). [ http:\/\/www.fda.gov\/bbs\/topics\/news\/2005\/NEW01171.html ] (accessed 20 August 2007)"},{"key":"BFncprheum0619_CR40","unstructured":"EMEA (online 27 June 2005) Press release. European medicines agency concludes action on COX2 inhibitors. [ http:\/\/www.emea.europa.eu\/pdfs\/human\/press\/pr\/20776605en.pdf ] (accessed 21 August 2007)"},{"key":"BFncprheum0619_CR41","unstructured":"EMEA (online 17 October 2005) Press release. European Medicines Agency update on non-selective NSAIDs. [ http:\/\/www.emea.europa.eu\/pdfs\/human\/press\/pr\/29896405en.pdf ] (accessed 21 August 2007)"},{"key":"BFncprheum0619_CR42","doi-asserted-by":"crossref","unstructured":"ADAPT Research Group (2006) Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 1: e33","DOI":"10.1371\/journal.pctr.0010033"},{"key":"BFncprheum0619_CR43","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302\u20131308","journal-title":"BMJ"},{"key":"BFncprheum0619_CR44","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J and Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366","journal-title":"BMJ"},{"issue":"Suppl III","key":"BFncprheum0619_CR45","first-page":"85","volume":"64","author":"G Singh","year":"2005","unstructured":"Singh G et al. (2005) Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Ann Rheum Dis 64 (Suppl III): 85","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0619_CR46","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP et al. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771\u20131781","journal-title":"Lancet"},{"key":"BFncprheum0619_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tips.2007.01.003","volume":"28","author":"NA Flavahan","year":"2007","unstructured":"Flavahan NA (2007) Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci 28: 106\u2013110","journal-title":"Trends Pharmacol Sci"},{"key":"BFncprheum0619_CR48","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/01.RES.0000153150.27690.f2","volume":"96","author":"K Rabausch","year":"2005","unstructured":"Rabausch K et al. (2005) Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX2-derived prostaglandins. Circ Res 96: e1\u2013e6","journal-title":"Circ Res"},{"key":"BFncprheum0619_CR49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","volume":"69","author":"IA Reilly","year":"1987","unstructured":"Reilly IA and FitzGerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69: 180\u2013186","journal-title":"Blood"},{"key":"BFncprheum0619_CR50","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1073\/pnas.96.1.272","volume":"96","author":"BF McAdam","year":"1999","unstructured":"McAdam BF et al. (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX2. Proc Natl Acad Sci USA 96: 272\u2013277","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncprheum0619_CR51","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)38195-9","volume":"289","author":"F Catella-Lawson","year":"1999","unstructured":"Catella-Lawson F et al. (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735\u2013741","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncprheum0619_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1067\/mcp.2002.126182","volume":"72","author":"JI Schwartz","year":"2002","unstructured":"Schwartz JI et al. (2002) Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72: 50\u201361","journal-title":"Clin Pharmacol Ther"},{"key":"BFncprheum0619_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00045391-200007030-00004","volume":"7","author":"A Whelton","year":"2000","unstructured":"Whelton A et al. (2000) Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 7: 159\u2013175","journal-title":"Am J Ther"},{"key":"BFncprheum0619_CR54","first-page":"714","volume":"30","author":"G Singh","year":"2003","unstructured":"Singh G et al. (2003) Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 30: 714\u2013719","journal-title":"J Rheumatol"},{"key":"BFncprheum0619_CR55","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755\u20131762","journal-title":"Lancet"},{"key":"BFncprheum0619_CR56","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","volume":"45","author":"ML Capone","year":"2005","unstructured":"Capone ML et al. (2005) Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45: 1295\u20131301","journal-title":"J Am Coll Cardiol"},{"key":"BFncprheum0619_CR57","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa003199","volume":"345","author":"F Catella-Lawson","year":"2001","unstructured":"Catella-Lawson F et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809\u20131817","journal-title":"N Engl J Med"},{"key":"BFncprheum0619_CR58","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","volume":"361","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM and Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361: 573\u2013574","journal-title":"Lancet"},{"key":"BFncprheum0619_CR59","unstructured":"FDA (online 8 September 2006) Science background paper: concomitant use of ibuprofen and aspirin: potential for attenuation of the anti-platelet effect of aspirin. [ http:\/\/www.fda.gov\/cder\/drug\/infopage\/ibuprofen\/default.htm ] (accessed 20 August 2007)"},{"key":"BFncprheum0619_CR60","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1096\/fj.06-8061com","volume":"21","author":"B Hinz","year":"2007","unstructured":"Hinz B et al. (2007) Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans \u2013 new insights into the pharmacology of an old analgesic. FASEB J 21: 2343\u20132351","journal-title":"FASEB J"},{"key":"BFncprheum0619_CR61","unstructured":"Hinz B et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J, in press"},{"key":"BFncprheum0619_CR62","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1161\/01.HYP.0000177437.07240.70","volume":"46","author":"JP Forman","year":"2005","unstructured":"Forman JP et al. (2005) Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 46: 500\u2013507","journal-title":"Hypertension"},{"key":"BFncprheum0619_CR63","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.105.595793","volume":"113","author":"AT Chan","year":"2006","unstructured":"Chan AT et al. (2006) Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113: 1578\u20131587","journal-title":"Circulation"},{"key":"BFncprheum0619_CR64","unstructured":"EMEA (2006) European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAIDs. Doc. Ref. EMEA\/413136\/2006"},{"key":"BFncprheum0619_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009740310004766","volume":"33","author":"K Brune","year":"2004","unstructured":"Brune K and Hinz B (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 33: 1\u20136","journal-title":"Scand J Rheumatol"},{"key":"BFncprheum0619_CR66","unstructured":"Therapeutic Goods Administration: Urgent advice regarding management of patients taking lumiracoxib [Prexige]. Safety alert. 13 August 2007 [ http:\/\/www.tga.gov.au\/alerts\/prexige.htm ]"},{"key":"BFncprheum0619_CR67","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/bmc.633","volume":"20","author":"O Cheremina","year":"2006","unstructured":"Cheremina O et al. (2006) A validated high-performance liquid chromatographic assay for determination of lumiracoxib in human plasma. Biomed Chromatogr 20: 1033\u20131037","journal-title":"Biomed Chromatogr"},{"key":"BFncprheum0619_CR68","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.bjp.0706078","volume":"144","author":"R Esser","year":"2005","unstructured":"Esser R et al. (2005) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144: 538\u2013550","journal-title":"Br J Pharmacol"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0619","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0619.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:25:15Z","timestamp":1737447915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["BFncprheum0619"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0619","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}